Lupus (most commonly systemic lupus erythematosus) is a chronic autoimmune disease in which the immune system attacks the body's own tissues, causing inflammation and potential organ damage. It can affect multiple systems including skin, joints, kidneys, lungs, heart, blood cells, and brain.
Phase I CARLYSLE trial data show CAR-T therapy obe-cel induces remission in severe refractory lupus with a favorable safety profile. Separate case report documents two successful pregnancies after dual-target CAR-T therapy with no transmission to infants.
Two new studies advance Lyme disease research: anti-lipid antibodies may enable earlier diagnosis and detect persistent symptoms, while cell wall changes in Borrelia burgdorferi offer insights into Lyme arthritis pathogenesis and potential treatment targets.
Eli Lilly and Company has agreed to acquire Orna Therapeutics for up to $2.4 billion in cash. The deal includes ORN-252, a clinical-trial-ready CD19-targeting in vivo CAR-T therapy for B cell-driven autoimmune diseases.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Eli Lilly announced the acquisition of Orna Therapeutics for up to $2.4 billion on February 9, 2026, gaining access to proprietary circular RNA technology and an "in vivo" CAR-T platform for immunology and oncology applications.
Researchers have developed modified CAR T cells that overcome prostaglandin E2 suppression in solid tumors and a selective therapy targeting IGHV4-34 that spares healthy immune cells, addressing key limitations in current treatments.
SCOPE 2026 in Orlando recognized innovation in clinical research with three awards programs, honoring Biogen's lupus webinar series, TrialScreen's site connection initiative, and Biorce's AI platform among 70 competing products.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602595 |
The BRIDGE Pain Study |
RECRUITING | |
| NCT07598396 |
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis |
RECRUITING | PHASE2 |
| NCT07302113 |
Complete Cognitive Intervention for cSLE |
RECRUITING | NA |
| NCT07282392 |
Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET) |
RECRUITING | NA |
| NCT07267091 |
The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study |
COMPLETED | |
| NCT07262983 |
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis |
RECRUITING | PHASE1 |
| NCT07134166 |
Cardiac Imaging in Systemic Disorders: the ORACLES Registry |
NOT_YET_RECRUITING | |
| NCT07128966 |
Direct to Patient Minimal Risk Biospecimen and Data Collection Research |
RECRUITING | |
| NCT07107659 |
Safety and Efficacy of ONT01 in Lupus |
RECRUITING | EARLY_PHASE1 |
| NCT06999109 |
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress |
NOT_YET_RECRUITING | NA |
